Crossmark

Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer

Crossref DOI link: https://doi.org/10.1038/s41388-018-0554-z

Published Online: 2018-10-23

Published Print: 2019-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wagner, Steve

Vlachogiannis, Georgios

De Haven Brandon, Alexis

Valenti, Melanie

Box, Gary

Jenkins, Liam

Mancusi, Caterina

Self, Annette

Manodoro, Floriana

Assiotis, Ioannis

Robinson, Penny

Chauhan, Ritika

Rust, Alistair G.

Matthews, Nik

Eason, Kate http://orcid.org/0000-0001-6903-9067
Khan, Khurum

Starling, Naureen

Cunningham, David

Sadanandam, Anguraj

Isacke, Clare M.

Kirkin, Vladimir

Valeri, Nicola

Whittaker, Steven R. http://orcid.org/0000-0001-9062-7947
License Information

Text and Data Mining valid from 2018-10-23
More Information

Article History

Received: 13 March 2018

Revised: 14 September 2018

Accepted: 14 September 2018

First Online: 23 October 2018

Change Date: 30 May 2019

Change Type: Correction

Change Details: A correction to this paper has been published and can be accessed via a link at the top of the paper.

Compliance with ethical standards

:

: DC received research funding from: Roche, Amgen, Celgene, Sanofi, Merck Serono, Novartis, AstraZeneca, Bayer, Merrimack, and MedImmune. AS has ownership interest (including patents) as a patent inventor for a patent entitled “Colorectal cancer classification with differential prognosis and personalized therapeutic responses” (patent number PCT/IB2013/060416).